Tonix Pharmaceuticals Holding Corp. (TNXP)
7.30
+0.02
(+0.27%)
USD |
NASDAQ |
Oct 09, 16:00
7.33
+0.03
(+0.41%)
After-Hours: 20:00
Tonix Pharmaceuticals Free Cash Flow : -160.40M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -160.40M |
| March 31, 2026 | -134.68M |
| December 31, 2025 | -107.25M |
| September 30, 2025 | -78.87M |
| June 30, 2025 | -67.35M |
| March 31, 2025 | -60.09M |
| December 31, 2024 | -61.19M |
| September 30, 2024 | -69.19M |
| June 30, 2024 | -75.63M |
| March 31, 2024 | -92.29M |
| December 31, 2023 | -111.31M |
| September 30, 2023 | -117.10M |
| June 30, 2023 | -122.66M |
| March 31, 2023 | -130.29M |
| December 31, 2022 | -144.84M |
| September 30, 2022 | -164.77M |
| June 30, 2022 | -152.96M |
| March 31, 2022 | -139.65M |
| December 31, 2021 | -109.95M |
| September 30, 2021 | -81.42M |
| June 30, 2021 | -81.90M |
| March 31, 2021 | -71.56M |
| December 31, 2020 | -59.33M |
| September 30, 2020 | -46.74M |
| June 30, 2020 | -32.91M |
| Date | Value |
|---|---|
| March 31, 2020 | -27.49M |
| December 31, 2019 | -26.81M |
| September 30, 2019 | -26.74M |
| June 30, 2019 | -24.86M |
| March 31, 2019 | -25.44M |
| December 31, 2018 | -23.56M |
| September 30, 2018 | -21.86M |
| June 30, 2018 | -21.86M |
| March 31, 2018 | -21.06M |
| December 31, 2017 | -19.08M |
| September 30, 2017 | -19.65M |
| June 30, 2017 | -23.08M |
| March 31, 2017 | -26.62M |
| December 31, 2016 | -37.38M |
| September 30, 2016 | -43.90M |
| June 30, 2016 | -47.86M |
| March 31, 2016 | -49.25M |
| December 31, 2015 | -42.76M |
| September 30, 2015 | -39.14M |
| June 30, 2015 | -31.80M |
| March 31, 2015 | -28.11M |
| December 31, 2014 | -23.12M |
| September 30, 2014 | -18.32M |
| June 30, 2014 | -16.17M |
| March 31, 2014 | -11.23M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Inovio Pharmaceuticals, Inc. | -80.78M |
| Nektar Therapeutics | -234.03M |
| Heron Therapeutics, Inc. | -12.14M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -41.87M |
| Cash from Investing (Quarterly) | -0.5769M |
| Cash from Financing (Quarterly) | 33.27M |
| Free Cash Flow Per Share (Quarterly) | -2.552 |
| Free Cash Flow to Equity (Quarterly) | -42.43M |
| Free Cash Flow to Firm (Quarterly) | -42.44M |
| Free Cash Flow Yield | -172.1% |